STAT

Should drug makers be banned from buying back stock? Take our reader poll

A new analysis finds many drug makers spent more on buying back stock and paying dividends than on research and development.

Drug makers often argue that innovation would suffer whenever they are attacked for high prices. But a new analysis finds many of these companies have actually spent more on buying

You're reading a preview, sign up to read more.

More from STAT

STAT3 min readPsychology
Opinion: Quitting Smoking Is Hard. Mindfulness Hacks The Habit Loop, Offering A New Approach
Smoking hijacks the brain's reward-based learning system. Each time a smoker smokes, it reinforces a brain pathway that says, "This is great, do it again." Mindfulness techniques can break the…
STAT2 min readPolitics
Sanders And Cummings, Citing ‘Polite F-u Letters,’ Urge Feds To Step Up Probes Of Generic Makers
Sen. Bernie Sanders (I-Vt.) and Rep. Elijah Cummings (D-Md.), citing 'polite f-u letters' from drug makers, urge feds to step up probes.
STAT5 min readWellness
After Ebola Spills Into Uganda, WHO Decides Against Emergency Declaration
The Ebola outbreak in the Democratic Republic of the Congo still doesn’t constitute a global health emergency, the WHO said Friday.